)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Elevation Oncology
Elevation Oncology (ELEV) investor relations material
Elevation Oncology has been acquired
Elevation Oncology Q1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2025 earnings summary15 May, 2025
Executive summary
Net loss of $14.2 million for Q1 2025, up from $10.7 million in Q1 2024, with an accumulated deficit of $254.7 million as of March 31, 2025.
Discontinued EO-3021 development and implemented a 70% workforce reduction to focus resources and evaluate strategic alternatives.
Focus shifted to advancing EO-1022, a HER3-targeting ADC, with IND filing expected in 2026 and promising preclinical data presented at AACR 2025.
Workforce reduction resulted in $3.4 million in restructuring charges.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $80.7 million as of March 31, 2025; expected to be $30M–$35M after loan prepayment and restructuring.
Research and development expenses were $6.9 million, up from $6.0 million year-over-year, mainly due to EO-1022 advancement.
General and administrative expenses were $4.0 million, slightly higher than $3.9 million in Q1 2024.
Net loss per share: $(0.24) for Q1 2025 vs. $(0.21) for Q1 2024.
Long-term debt was $31.3 million at quarter-end, fully prepaid in May 2025.
Outlook and guidance
Cash runway expected to fund operations into the second half of 2026, but additional capital will be needed for further development and commercialization.
IND filing for EO-1022 planned for 2026, with continued investment in preclinical and IND-enabling activities.
Company is evaluating strategic alternatives, including potential mergers, asset sales, or licensing deals.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Elevation Oncology
- EO-3021 shows robust efficacy and safety, with new combination and HER3 ADC programs advancing.ELEV
Piper Sandler 36th Annual Healthcare Conference - EO-3021 achieved 42.8% ORR and strong safety in Claudin 18.2-enriched gastric/GEJ cancers.ELEVStudy Update
- EO-3021 shows strong early efficacy and safety, with funding secured into 2026.ELEVQ3 2024
- EO-3021 shows strong early results in Claudin 18.2-positive cancers, with robust funding into 2026.ELEVH.C. Wainwright 26th Annual Global Investment Conference 2024
- EO-3021 achieved 42.8% ORR in Phase 1; $110.8M cash funds operations into 2026.ELEVQ2 2024
- EO-3021 demonstrates strong efficacy and safety, with pivotal data and expansion plans set for 2025.ELEVTD Cowen 45th Annual Healthcare Conference
- EO-3021 and EO-1022 pipeline progress drives R&D investment, with cash runway into 2026.ELEVQ4 2024
Elevation Oncology
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Elevation Oncology, Inc. is a biotechnology company focused on the discovery and development of targeted cancer therapies. The company specializes in creating antibody-drug conjugates (ADCs) to treat patients with solid tumors that have significant unmet medical needs. Their lead candidate, EO-3021, targets the Claudin 18.2 protein, which is expressed in various cancers, including gastric and pancreatic cancers. Elevation Oncology aims to selectively deliver cytotoxic agents directly to cancer cells, thereby improving treatment efficacy while minimizing damage to healthy tissues. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.